文献速递妇科

艾拉戈利联合反向添加疗法治疗子宫内膜异位症相关疼痛的疗效、耐受性及骨密度结局:一项正在进行的随机3期试验的12个月结果

Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial.
PubMed 文献 · Am J Obstet Gynecol · 2024-06-30

这项正在进行的48个月3期试验将679例子宫内膜异位症相关疼痛的绝经前女性按4:1:2随机分为艾拉戈利200mg每日两次联合反向添加疗法组、艾拉戈利单药治疗6个月后联合反向添加疗法组或安慰剂组。与安慰剂相比,联合组在6个月时痛经和非经期盆腔痛的临床改善率显著更高,并持续至12个月;联合组骨密度变化小于1%,且较单药组骨丢失减轻。

要点

  • 艾拉戈利联合反向添加疗法组6个月痛经应答率62.8% vs 安慰剂组23.7%(P≤.001)。
  • 联合组6个月非经期盆腔痛应答率51.3% vs 安慰剂组36.8%(P≤.001)。
  • 联合组12个月骨密度变化<1%,单药组6个月腰椎骨密度下降2.43%。

核心结论

  • 与安慰剂相比,艾拉戈利联合反向添加疗法在6个月时对痛经、非经期盆腔痛和疲劳产生显著且有临床意义的改善,其中痛经和非经期盆腔痛的改善持续至12个月。
  • 艾拉戈利联合反向添加疗法总体耐受性良好。
  • 12个月时联合组骨密度丢失大于安慰剂组,但联合组骨密度变化<1%,且较艾拉戈利单药治疗观察到的骨丢失减轻。

研究设计与样本

  • 这项正在进行的48个月3期研究包含12个月双盲期,按4:1:2随机分为艾拉戈利200mg每日两次联合反向添加疗法组、艾拉戈利200mg每日两次单药治疗6个月后联合反向添加疗法组或安慰剂组。
  • 共679例患者被随机分配至联合组(n=389)、单药组(n=97)或安慰剂组(n=193)。
  • 共同主要终点为6个月时痛经和非经期盆腔痛达到临床改善(称为「应答者」)的患者比例。

主要发现

  • 6个月时,联合组痛经临床改善应答率62.8% vs 安慰剂组23.7%(P≤.001)。
  • 6个月时,联合组非经期盆腔痛临床改善应答率51.3% vs 安慰剂组36.8%(P≤.001)。
  • 与安慰剂相比,联合组在7个按层级排序的次要终点上较基线改善显著更大,包括痛经(第12、6、3个月)、非经期盆腔痛(第12、6、3个月)和疲劳(第6个月)(均P<.01)。
  • 总体不良事件发生率联合组为73.8%,安慰剂组为66.8%;严重和重度不良事件率组间无有意义差异;因不良事件停药率联合组为12.6%,安慰剂组为9.8%。
  • 单药组6个月时骨密度较基线下降:腰椎-2.43%、全髋-1.54%、股骨颈-1.78%;单药组第6个月加用反向添加疗法后,12个月时骨密度变化仍处于-1.58%至-1.83%的相似范围;而从基线即接受联合治疗的患者6个月和12个月时骨密度较基线变化很小(<1%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE: To evaluate efficacy, tolerability, and bone density outcomes of elagolix 200 mg twice daily with 1 mg estradiol/0.5 mg norethindrone acetate (add-back) therapy once daily compared with placebo in premenopausal women with moderate-to-severe endometriosis-associated pain. STUDY DESIGN: This ongoing, 48-month, phase 3 study consists of a 12-month double-blind period, with randomization 4:1:2 to elagolix 200 mg twice daily with add-back therapy, elagolix 200 mg twice daily monotherapy for 6 months followed by elagolix with add-back therapy, or placebo. The coprimary endpoints were proportion of patients with clinical improvement (termed "responders") in dysmenorrhea and nonmenstrual pelvic pain at month 6. We report 12-month results on efficacy of elagolix with add-back therapy vs placebo in reducing dysmenorrhea, nonmenstrual pelvic pain, dyspareunia, and fatigue. Tolerability assessments include adverse events and change from baseline in bone mineral density. RESULTS: A total of 679 patients were randomized to elagolix with add-back therapy (n=389), elagolix monotherapy (n=97), or placebo (n=193). Compared with patients randomized to placebo, a significantly greater proportion of patients randomized to elagolix with add-back therapy responded with clinical improvement in dysmenorrhea (62.8% vs 23.7%; P≤.001) and nonmenstrual pelvic pain (51.3% vs 36.8%; P≤.001) at 6 months. Compared with placebo, elagolix with add-back therapy produced significantly greater improvement from baseline in 7 hierarchically ranked secondary endpoints including dysmenorrhea (months 12, 6, 3), nonmenstrual pelvic pain (months 12, 6, 3), and fatigue (months 6) (all P<.01). Overall, the incidence of adverse events was 73.8% with elagolix plus add-back therapy and 66.8% with placebo. The rate of severe and serious adverse events did not meaningfully differ between treatment groups. Study drug discontinuations associated with adverse events were low in patients receiving elagolix with add-back therapy (12.6%) and those receiving placebo (9.8%). Patients randomized to elagolix monotherapy exhibited decreases from baseline in bone mineral density of -2.43% (lumbar spine), -1.54% (total hip), and -1.78% (femoral neck) at month 6. When add-back therapy was added to elagolix at month 6, the change from baseline in bone mineral density remained in a similar range of -1.58% to -1.83% at month 12. However, patients who received elagolix plus add-back therapy from baseline exhibited little change from baseline in bone mineral density (<1% change) at months 6 and 12. CONCLUSION: Compared with placebo, elagolix with add-back therapy resulted in significant, clinically meaningful improvement in dysmenorrhea, nonmenstrual pelvic pain, and fatigue at 6 months that continued until month 12 for both dysmenorrhea and nonmenstrual pelvic pain. Elagolix with add-back therapy was generally well tolerated. Loss of bone mineral density at 12 months was greater in patients who received elagolix with add-back therapy than those who received placebo. However, the change in bone mineral density with elagolix plus add-back therapy was <1% and was attenuated compared with bone loss observed with elagolix monotherapy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Miller CE, Kim JH, Kroll R, et al. Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial. Am J Obstet Gynecol. 2024. PMID: 38955323. doi:10.1016/j.ajog.2024.06.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。